Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Combigan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Background The purpose of this study was to evaluate the safety and efficacy of a fixed combination of timolol maleate 0.5… Expand
  • table 1
  • figure 1
Is this relevant?
2013
2013
  • C. Harrison
  • Nature Reviews Drug Discovery
  • 2013
  • Corpus ID: 29970897
glaucoma drug Combigan (brimonidine and timolol) even though a US court ruled that a patent that describes the combination of… Expand
  • table 1
Is this relevant?
2011
2011
  • 2011
  • Corpus ID: 32553269
Brimonidine tartrate is an alpha-2 selective adrenergic receptor agonist for ophthalmic use. Brimonidine tartrate is a white to… Expand
  • table 1
  • table 2
Is this relevant?
2011
2011
PURPOSE This study was undertaken to compare the ocular haemodynamic effects of Combigan(®) versus placebo in patients with… Expand
Is this relevant?
2008
2008
Lowering IOP is the most readily modifiable risk factor to delay the development and progression of glaucoma (POAG). The fixed… Expand
Is this relevant?
2008
2008
  • JAAPA : official journal of the American Academy…
  • 2008
  • Corpus ID: 672674
 
Is this relevant?
2007
2007
Purpose. Data are provided from the Combigan Early Experience Data (CEED) study, which evaluated patients’ clinical experience of… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2005
2005
Objective:  To compare the costs of the new fixed combinations for glaucoma medical therapy. 
Is this relevant?